



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	09/674,794
				Filing Date	August 21, 2001
				First Named Inventor	Melvyn Little
				Art Unit	1642
Examiner Name	Unknown				
Sheet	1	of	1	Attorney Docket Number	31304-756.831

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
PKT		US-6,759,518	07/06/2004	Roland Kontermann, <i>et al.</i>	
PKT		US2005/0004352 A1	01/06/2005	Roland Kontermann, <i>et al.</i>	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
PKT		EP 0 952 218 A2	10/27/1999	Roland Kontermann, <i>et al.</i>		

Examiner Signature	<i>P.B. [Signature]</i>	Date Considered	9/9/05
--------------------	-------------------------	-----------------	--------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

LIST OF REFERENCES CITED BY APPLICANT <i>(Use several sheets if necessary)</i>				ATTY. DOCKET NO.		APPLICATION NO.	
				8484-089-999		09/674,794	
				APPLICANT			
				Little <i>et al.</i>			
				FILING DATE		GROUP	
				November 3, 2000		To be assigned	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)							
PKT	AA	Gruber <i>et al.</i> , 1994, "Efficient tumor cell lysis mediated by a bispecific single chain antibody expressed in <i>Escherichia coli</i> ", <i>Journal of Immunology</i> 10:5368-5374.					
	AB	Mack <i>et al.</i> , 1995, "A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity", <i>Proceedings of the National Academy of Sciences of the United States of America</i> 92:7021-7025.					
	AC	Kurucz <i>et al.</i> , 1995, "Retargeting f CTL by an efficiently refolded bispecific single-chain Fv dimer produced in bacteria", <i>Journal of Immunology</i> 154:4576-4582.					
	AD	De Jonge <i>et al.</i> , 1995, "Production and characterization of bispecific single-chain antibody fragments", <i>Molecular Immunology</i> 32:1405-1412.					
	AE	Coloma <i>et al.</i> , "Design and production of novel tetravalent bispecific antibodies", <i>Nature Biotechnology</i> 15:159-163.					
	AF	Kipriyanov <i>et al.</i> , 1999, "Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics", <i>Journal of Molecular Biology</i> 293:41-56.					
	AG	Kipriyanov <i>et al.</i> , 1996, <i>J-Immunol. Meth.</i> 196:51-62.					
	AH	Kipriyanov <i>et al.</i> , 1997, <i>Protein Eng.</i> 10:445-453.					
EXAMINER				DATE CONSIDERED			
P. G. [Signature]				9/9/5			
<small>*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							